LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody^® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 26^th Annual Global Investment Conference.